Featured Research

from universities, journals, and other organizations

Research Improves Treatment Of Bladder Cancer

Date:
April 25, 2001
Source:
Ohio State University
Summary:
Researchers have found a relatively simple way to dramatically improve the cancer-killing capacity of a drug often used to treat superficial bladder cancer. The changes nearly doubled the number of people who were cancer-free after five years, compared to those receiving the standard therapy, and lengthened the time before tumors recurred in these patients.

COLUMBUS, Ohio - Researchers have found a relatively simple way to dramatically improve the cancer-killing capacity of a drug often used to treat superficial bladder cancer.

The changes nearly doubled the number of people who were cancer-free after five years, compared to those receiving the standard therapy, and lengthened the time before tumors recurred in these patients.

The finding is the result of a five-year, international study published in the April 18 issue of the Journal of the National Cancer Institute.

The study looked at ways to improve the use of mitomycin C (MMC) following surgical removal of the tumor. In both the standard and the experimental therapy, MMC is placed in the bladder where it is held by the patient for about two hours.

The new therapy, however, took special measures to maintain a high drug concentration in the bladder.

"We compared the usual way of giving the drug to a new approach, said Jessie L-S Au, distinguished university professor and Dorothy M. Davis Chair in Cancer Research at the College of Pharmacy at Ohio State University.

Patients receiving the experimental treatment went an average of 29.1 months before their cancer recurred, while those receiving the standard treatment had recurrence in 11.3 months.

There was also a statistically significant difference in the number of patients who were recurrence-free after five years: 42.6 percent in the modified treatment versus 23.5 receiving standard treatment.

"We have found a way to make this treatment more effective in a highly significant way," said Au, a researcher with Ohio State's Comprehensive Cancer Center. "We nearly doubled the percentage of patients who were disease-free after five years."

The study, done by Au and a team of researchers, involved 230 patients with confirmed superficial bladder cancer who were at high risk of recurrence. Of these, 111 patients received standard treatment and 119 received the experimental therapy.

For the standardized therapy, urine was drained from the bladder using a catheter. Then, a 20-mg dose of MMC was placed in the bladder, where it was held for two hours. No special steps were taken to reduce the remaining volume or to reduce urine acidity.

The experimental therapy used a 40-mg dose of MMC and several steps were taken to maintain a high drug concentration in the bladder by reducing urine volume.

For example, patients were instructed to abstain from drinking water prior to and during treatment to reduce urine production. Steps were also taken to drain as much urine from bladder as possible just prior to treatment.

Lastly, patients were given doses of sodium bicarbonate to reduce urine acidity, a factor known to inactivate MMC.

Next, Au will also try to improve the efficacy of MMC further by using an additional drug to make the tumor more sensitive to the drug. Au's study was sponsored by the National Cancer Institute and was done in conjunction with The Ohio State University Comprehensive Cancer Center.

Sidebar -- STUDY OF ANTI-CANCER DRUG HAS IMPORTANT IMPLICATIONS FOR AFRICAN-AMERICANS

The Ohio State study on MMC had an unexpected finding that has important implications for African Americans with superficial bladder cancer, and possibly other cancers.

The five-year, multi-institutional study, led by Jessie L-S Au, distinguished university professor and Dorothy M. Davis Chair in Cancer Research at the College of Pharmacy at Ohio State University, demonstrated a way to significantly improve the effectiveness of the drug.

Of the 230 people involved in the research, six were African Americans. Three of these patients were randomly selected to receive the standard therapy and three the modified therapy.

Regardless of treatment, however, all six people experienced a recurrence of their disease in less than one year. The difference between the African-American and the Caucasian data was highly statistically significant, said Au, but because the number of African-American patients was so low, no firm conclusions can be drawn from the outcome.

Based on this outcome, however, "mitomycin C doesn't seem like a good drug for African Americans, and an alternative drug should be tried," said Au. "I can't say which drug, though, because no one looks at race as a risk factor in clinical trials."

Au's finding indicates that should change. "This data is strong evidence that we should study race as a risk factor," she said. "Perhaps the difference is genetic. African Americans may lack the two enzymes in the body that make this drug work." Au plans to study archived tissues from African-American patients for presence of the enzymes.


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "Research Improves Treatment Of Bladder Cancer." ScienceDaily. ScienceDaily, 25 April 2001. <www.sciencedaily.com/releases/2001/04/010418072710.htm>.
Ohio State University. (2001, April 25). Research Improves Treatment Of Bladder Cancer. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2001/04/010418072710.htm
Ohio State University. "Research Improves Treatment Of Bladder Cancer." ScienceDaily. www.sciencedaily.com/releases/2001/04/010418072710.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins